نتائج البحث - "Monoclonal/administration & dosage"

1

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

المصدر: Dimopoulos, M A, Oriol, A, Nahi, H, San-Miguel, J, Bahlis, N J, Usmani, S Z, Rabin, N, Orlowski, R Z, Komarnicki, M, Suzuki, K, Plesner, T, Yoon, S-S, Ben Yehuda, D, Richardson, P G, Goldschmidt, H, Reece, D, Lisby, S, Khokhar, N Z, O'Rourke, L, Chiu, C, Qin, X, Guckert, M, Ahmadi, T, Moreau, P & POLLUX Investigators 2016, ' Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma ', The New England Journal of Medicine, vol. 375, no. 14, pp. 1319-1331 . https://doi.org/10.1056/NEJMoa1607751Test

مصطلحات موضوعية: Dexamethasone/administration & dosage, Oncology, medicine.medical_specialty, Multiple Myeloma/drug therapy, Kaplan-Meier Estimate, Antibodies, Monoclonal/administration & dosage, Disease-Free Survival, Ixazomib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Recurrence, Internal medicine, Humans, Medicine, Elotuzumab, Lenalidomide, Multiple myeloma, Dexamethasone, Aged, Thalidomide/administration & dosage, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Daratumumab, General Medicine, Middle Aged, Pomalidomide, medicine.disease, Interim analysis, Surgery, chemistry, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, business, 030215 immunology, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a61628e9bf3047e8da229f84c6cb1962Test
https://doi.org/10.1056/nejmoa1607751Test

2

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

المؤلفون: Ajai Chari, Torben Plesner, Nizar J. Bahlis, Paul G. Richardson, A. Kate Sasser, Imran Khan, Henk M. Lokhorst, Jianping Wang, Saad Z. Usmani, Andrew Belch, Amy Axel, Hareth Nahi, Sagar Lonial, Clarissa M. Uhlar, Peter M. Voorhees, Huaibao Feng, Brendan M. Weiss, Tahamtan Ahmadi

المساهمون: Hematology, CCA - Clinical Therapy Development

المصدر: Usmani, S Z, Weiss, B M, Plesner, T, Bahlis, N J, Belch, A, Lonial, S, Lokhorst, H M, Voorhees, P M, Richardson, P G, Chari, A, Sasser, A K, Axel, A, Feng, H, Uhlar, C M, Wang, J, Khan, I, Ahmadi, T & Nahi, H 2016, ' Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma ', Blood, vol. 128, no. 1, pp. 37-44 . https://doi.org/10.1182/blood-2016-03-705210Test
Blood, 128(1), 37-44. American Society of Hematology

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Clinical Trials and Observations, Immunology, Population, Multiple Myeloma/drug therapy, Phases of clinical research, 030204 cardiovascular system & hematology, Biochemistry, Gastroenterology, Antibodies, Monoclonal/administration & dosage, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Refractory, Recurrence, Internal medicine, medicine, Humans, education, Survival rate, Aged, Aged, 80 and over, education.field_of_study, business.industry, Remission Induction, Antibodies, Monoclonal, Daratumumab, Cell Biology, Hematology, Middle Aged, medicine.disease, Confidence interval, Surgery, Survival Rate, 030220 oncology & carcinogenesis, Absolute neutrophil count, Female, Multiple Myeloma, business, Progressive disease, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f295fc13f374ff3f19aa41f321afe70cTest
https://portal.findresearcher.sdu.dk/da/publications/54cae8bd-1c4c-436d-9c67-415c1f9d781aTest

3

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

المساهمون: Hematology, Hematology laboratory, CCA - Innovative therapy

المصدر: Lokhorst, H M, Plesner, T, Laubach, J P, Nahi, H, Gimsing, P, Hansson, M, Minnema, M C, Lassen, U, Krejcik, J, Palumbo, A, van de Donk, N W C J, Ahmadi, T, Khan, I, Uhlar, C M, Wang, J, Sasser, A K, Losic, N, Lisby, S, Basse, L, Brun, N & Richardson, P G 2015, ' Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma ', New England Journal of Medicine, vol. 373, no. 13, pp. 1207-1219 . https://doi.org/10.1056/NEJMoa1506348Test
New England Journal of Medicine, 373(13), 1207. Massachussetts Medical Society
New England Journal of Medicine, 373(13), 1207-1219. Massachussetts Medical Society
Lokhorst, H M, Plesner, T, Laubach, J P, Nahi, H, Gimsing, P, Hansson, M, Minnema, M C, Lassen, U, Krejcik, J, Palumbo, A, van de Donk, N, Ahmadi, T, Khan, I, Uhlar, C M, Wang, J, Sasser, A K, Losic, N, Lisby, S, Basse, L, Brun, N & Richardson, P G 2015, ' Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma ', The New England Journal of Medicine, vol. 373, no. 13, pp. 1207-1219 . https://doi.org/10.1056/NEJMoa1506348Test

مصطلحات موضوعية: Male, Drug Resistance, Gastroenterology, Clinical Trial, Phase II, Monoclonal, ADP-ribosyl Cyclase 1/antagonists & inhibitors, Elotuzumab, Non-U.S. Gov't, Multiple myeloma, Isatuximab, Medicine(all), Thrombocytopenia/chemically induced, Bortezomib, Medicine (all), Pneumonia/chemically induced, Research Support, Non-U.S. Gov't, Antibodies, Monoclonal, General Medicine, Middle Aged, Clinical Trial, Phase II, Antineoplastic Agents/administration & dosage, Multicenter Study, Female, Drug, Multiple Myeloma, medicine.drug, Adult, medicine.medical_specialty, Multiple Myeloma/drug therapy, Antineoplastic Agents, Research Support, Antibodies, Monoclonal/administration & dosage, Antibodies, Disease-Free Survival, Clinical Trial, Phase I, Aged, Antigens, CD38, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Humans, Pneumonia, Thrombocytopenia, Dose-Response Relationship, Phase I, Refractory, Internal medicine, medicine, Journal Article, Antigens, Adverse effect, Lenalidomide, MONOCLONAL-ANTIBODY ANTITUMOR-ACTIVITY MULTICENTER BORTEZOMIB ELOTUZUMAB SAR650984 THERAPIES SURVIVAL PROTEIN CELLS, business.industry, Daratumumab, medicine.disease, ADP-ribosyl Cyclase 1, Surgery, Neoplasm, business, CD38